Phase 1b clinical trial of Starget's lead theranostic, DOTA-PTR-58 for sarcomas, neuroendocrine tumors (NET), melanoma, and hepatocellular carcinomas.
Latest Information Update: 29 Apr 2025
At a glance
- Drugs 225Ac PTR 58 (Primary)
- Indications Liver cancer; Malignant melanoma; Neuroendocrine tumours; Sarcoma
- Focus Adverse reactions
Most Recent Events
- 29 Apr 2025 The MR mentions The trial will be conducted at MD Anderson and other centers hence I didn't assumed the location for now
- 29 Apr 2025 New trial record
- 23 Oct 2024 According to Starget Pharma media release, the company received $5.1 million investment from Cancer Focus Fund to support a Phase 1b clinical trial of DOTA-PTR-58.The trial will be conducted at MD Anderson and other centers and will begin enrolling patients in early 2025.Jordi Rodon will be the Principal Investigator of this study.